Per thor Straten | Scientific Advisor and co-founder
Per thor Straten has an MSc in Biology and is a Clinical Professor at the University of Copenhagen. He is a scientific adviser to the company, and a co-founder of RhoVac. Straten has extensive research experience in the fields of immunotherapy, specifically therapeutic cancer vaccines. Mr. Straten has authored numerous scientific articles relating to tumour immunology and immunotherapy. He was involved in the successful exit of SurVac ApS.
Mads Hald Andersen | Scientific Advisor and co-founder
Mads Hald Andersen has an MSc in Engineering, a PhD, and is a Clinical Professor at the University of Copenhagen. Mr. Hald Andersen is a scientific advisor to the company, and a co-founder of RhoVac. He has wide research experience in the field of immunotherapy, specifically therapeutic cancer vaccines, and has authored numerous scientific articles on tumour immunology and immunotherapy. He was involved in the successful exit of SurVac ApS.
Gustav Gaudernack | Scientific Advisor
Professor Gustav Gaudernack is a leading researcher in the development of cancer vaccines and cancer immunotherapy. Throughout his career, Mr. Gaudernack has developed various strategies for immunological treatment of cancer. He is participating actively in several ongoing cellular and immuno-/gene- therapy clinical trials, and his research group has contributed hugely to the development of various T-cell based immunotherapy strategies.
Inge Marie Svane | Medical Advisor
Inge Marie Svane is a Professor in Clinical Cancer Immunotherapy and Head of the translational research centre, Research Center for Cancer Immune Therapy (CCIT), at Herlev University Hospital in Denmark. She has extensive experience in preclinical research as well as in clinical trials of experimental immunotherapies.